Assertio Holdings

Rolvedon And Sympazan Will Open New Healthcare Frontiers

AnalystConsensusTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

28 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$2.63

70.1% undervalued

15 Aug

US$0.79

-38.6%

-3.4%

Author's Valuation

US$2.6

70.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Decreased 6.25%

AnalystConsensusTarget Fair Value

US$2.6

70.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.27%

Pharma revenue growth rate

0.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$15.73m

Earnings '28

19.91x

PE Ratio '28

US$313.17m

Market Cap '28

US$313.17m

Market Cap '28

99.00m

No. shares '28

US$3.16

Share Price '28

US$3.16 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$2.60

Fair Value '25

Rolvedon And Sympazan Will Open New Healthcare Frontiers

Shared on01 May 25Fair value Decreased 6.25%

Shared on01 May 25
Fair value Decreased 6.25%